Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.
- Published In:
- Journal of affective disorders, 389, 119670 (2025)
- Authors:
- Wang, Min(4), Yang, Zhiyun, Yan, Min, Liu, Shao, Xiao, Sa
- Database ID:
- RPEP-14027
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14027APA
Wang, Min; Yang, Zhiyun; Yan, Min; Liu, Shao; Xiao, Sa. (2025). Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.. Journal of affective disorders, 389, 119670. https://doi.org/10.1016/j.jad.2025.119670
MLA
Wang, Min, et al. "Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.." Journal of affective disorders, 2025. https://doi.org/10.1016/j.jad.2025.119670
RethinkPeptides
RethinkPeptides Research Database. "Depression and suicide/self-injury signals for weight loss m..." RPEP-14027. Retrieved from https://rethinkpeptides.com/research/wang-2025-depression-and-suicideselfinjury-signals
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.